Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| 2'-O,4'-C-Methyleneguanosine | 2'-O,4'-C-Methyleneguanosine, a modified nucleoside molecule, has demonstrated effective outcomes in the domain of antiviral therapeutics, exemplifying excellent potential as a therapeutic agent for hepatitis C and West Nile virus infections. Substantiated by its unique mechanism of action- hindering viral RNA polymerase, a critical enzyme necessary for viral replication, it is deemed a highly potent approach for viral inhibition. Furthermore, this particular compound presents an enticing opportunity for its application as an antitumor agent, drawing interest from scientific communities. Group: Pharmaceutical. CAS No. 207131-16-6. Pack Sizes: 100 mg. Product ID: B2706-038100. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| (2'R)-2'-deoxy-2'-fluoro-2'-C-methyluridine | PSI-6206 is a selective HCV RNA polymerase inhibitor. It is the unphosphorylated parent compound of triphosphate analog PSI-7409, which is a potent inhibitor of the HCV NS5B RNA dependent RNA polymerase. Group: Pharmaceutical. CAS No. 863329-66-2. Pack Sizes: 5 g. Product ID: B2693-459960. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3'-Azido-3'-deoxyguanosine | 3'-Azido-3'-deoxyguanosine is an exceptionally robust antiviral compound meticulously formulated to intricately impede the microbial replication process by precisely directing its attention towards the viral DNA polymerase, disallowing its maleficent progression. Expertly synthesized, this quintessential nucleoside analogue incessantly finds application within the biomedical sector for its unprecedented multiplicity within research domains pertaining to antiviral pharmaceutical evolution and the efficacious research of viral ailments, most notably retroviruses and herpes viruses induced afflictions. Group: Pharmaceutical. CAS No. 98870-11-2. Pack Sizes: 50 mg. Product ID: B1370-064370. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3'-Deoxythymidine | 3'-Deoxythymidine is a precursor of DNA polymerase β inhibitor. Group: Pharmaceutical. CAS No. 3416-5-5. Pack Sizes: 1 g. Product ID: B1370-090563. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3'-O-(2-Methoxyethyl)guanosine | 3'-O-(2-Methoxyethyl)guanosine is a remarkable modified nucleoside with immense potential in the field of antiviral drug discovery. This exquisite compound takes center stage in targeting viral RNA-dependent RNA polymerases, thus rendering it a powerful weapon in research of respiratory syncytial virus (RSV) and hepatitis C virus (HCV). Group: Pharmaceutical. CAS No. 256224-03-0. Pack Sizes: 2 g. Product ID: B1370-038131. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 4'-a-C-Methyluridine | 4'-a-C-Methyluridine, a vital element in biomedical exploration and pharmacological progress, finds significance as it exhibits therapeutic capabilities in addressing a diverse spectrum of ailments, including hepatitis C, cancer, and viral infections. Notably, this compound exerts its impact by effectively obstructing RNA polymerase, thereby impeding viral replication and fostering potent antitumor influences. Group: Pharmaceutical. CAS No. 153186-26-6. Pack Sizes: 5 mg. Product ID: B2706-339917. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 5-Iodo-2'-deoxytubercidin | It is a derivative of 7-Iodo-7-deazadenine and is designed to be incorporated into DNA by using Vent(exo-) polymerase primers extension. Uses: Pharmaceutical intermediates. Group: Pharmaceutical. CAS No. 166247-63-8. Pack Sizes: 500 mg. Product ID: B0001-331316. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 7-Deaza-2'-C-methyladenosine | 7-Deaza-2'-C-methyladenosine is a hepatitis C virus (HCV) polymerase inhibitor. Uses: Hepatitis c virus (hcv) polymerase inhibitor. Group: Pharmaceutical. CAS No. 443642-29-3. Pack Sizes: 100 mg. Product ID: B2693-142324. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AOH1996 | AOH1996 is a small-molecule PCNA inhibitor that enhances the interaction between PCNA and the largest subunit of RNA polymerase II, RPB1, and dissociates PCNA from actively transcribed chromatin regions, while inducing DNA double-stranded breaks in a transcription-dependent manner. AOH1996 was identified as a selective chemotherapeutic. Group: Pharmaceutical. CAS No. 2089314-64-5. Pack Sizes: 100 mg. Product ID: B1370-426615. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ART558 | ART558 is a nanomolar potent, selective, allosteric DNA polymerase activity of Polθ inhibitor with IC50 of 7.9 nM. ART558 can be used in cancer research. Group: Pharmaceutical. CAS No. 2603528-97-6. Pack Sizes: 5 mg. Product ID: B1370-410227. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ART812 | ART812 is an orally active DNA polymerase Polθ inhibitor with IC 50 of 7.6 nM. ART812 also significantly inhibited PARP-resistant BRCA1 mutant tumor growth in rats. Group: Pharmaceutical. CAS No. 2607138-82-7. Pack Sizes: 50 mg. Product ID: B1370-410226. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Bakuchiol | Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L with anti-tumor, antioxidant, and antibacterial effects. Bakuchiol has a retinol-like effect on skin gene expression and properties. Bakuchiol inhibits DNA polymerase and UDP-glucuronosyltransferase 2B7 (IC50 = 41 μM). Bakuchiol has hypoglycemic, hypolipidemic, anti-inflammatory, anti-wrinkle, soothing and liver protective, anticancer, antidepressant, and estrogen-like effects. Uses: Antioxidant. Group: Pharmaceutical. CAS No. 10309-37-2. Pack Sizes: 100 mg. Product ID: NP4619. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Baloxavir | Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. CAS No. 1985605-59-1. Pack Sizes: 50 mg. Product ID: B2692-008721. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Baloxavir-[d4] | Baloxavir-[d4] is an isotope compound of Baloxavir. Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. CAS No. 2415027-80-2. Pack Sizes: 2 mg. Product ID: BLP-003387. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Baloxavir marboxil | Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration. Group: Pharmaceutical. CAS No. 1985606-14-1. Pack Sizes: 50 mg. Product ID: B2692-291710. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| β-Nicotinamide Adenine Dinucleotide | NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It plays a role in the activity of several enzymes, such as poly(ADP)-ribose polymerases and cADP-ribose synthases. NAD+ is commonly used as an oxidizing agent. Nutritional supplement in health care products. Uses: Ingredient of health care products. Group: Pharmaceutical. CAS No. 53-84-9. Pack Sizes: 10 g. Product ID: B0084-094034. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| BMS-791325 HCl | BMS-791325 HCl is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50 < 28 nM). In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. BMS-791325 was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation. BMS-791325 is currently under Phase III trials. Group: Pharmaceutical. CAS No. 958002-36-3. Pack Sizes: 5 mg. Product ID: B0084-462269. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Cidofovir dihydrate | Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. Uses: Antiviral agents. Group: Pharmaceutical. CAS No. 149394-66-1. Pack Sizes: 250 mg. Product ID: BBF-03991. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| dasabuvir | Dasabuvir is an antiviral drug for the treatment of hepatitis C. It inhibits hepatitis C virus (HCV) non-nucleoside NS5B palm polymerase to suppress RNA replicase. Dasabuvir is commonly used in combination with ombitasvir/paritaprevir/ritonavir to effect on HCV type 1. Uses: The treatment of hepatitis c. Group: Pharmaceutical. CAS No. 1132935-63-7. Pack Sizes: 100 mg. Product ID: B0084-462255. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Icaritin | Icaritin is unable to promote proliferation, migration and tube-like structure formation by human umbilical vein endothelial cells (HUVECs) in vitro. Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 μM) and primary CML cells (IC50 was 13.4 μM for CML-CP and 18 μM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML) and Imatinib-resistant cells, and to induce apoptosis. Icaritin strongly inhibited the growth of breast cancer MDA-MB-453 and MCF7 cells. At concentrations of 2-3 μM, icaritin induced cell cycle arrest at the G(2)/M phase accompanied by a down-regulation of the expression levels of the G(2)/M regulatory proteins such as cyclinB, cdc2 and cdc25C. Icaritin at concentrations of 4-5 μM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression. In mouse leukemia model, Icaritin could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells as effective as Imatinib without suppression of bone marrow. Icaritin could up-regulate phospho-JNK or phospho-C-Jun and down-regulate phospho-ERK, phospho-P-38, Jak-2, phospho-Stat3 and phospho-Akt expression with dose- or ti | London |
| Letermovir | Letermovir is a novel anti-CMV compound which targets the pUL56 (amino acid 230-370) subunit of the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. It has a novel mode of action targets the enzyme UL56 terminase and keep active to other drug-resistant virus. It has been approved in prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Uses: Antiviral agents. Group: Pharmaceutical. CAS No. 917389-32-3. Pack Sizes: 5 mg. Product ID: B2693-460490. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N1-MethylpseudoUridine-5'-Triphosphate Sodium | It is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase. Incorporation of N1-methylpseudouridine can reduce the immunogenicity of the resulting mRNA. The product has passed the functionality test in transcription reaction. The solution is free of DNase and RNase contamination. Group: Pharmaceutical. Pack Sizes: 1 mL. Product ID: B2706-358101. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Acetyl-5'-O-(4,4-dimethoxytrityl)-2'-O-methylcytidine-3'-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite | N-Acetyl-5'-O-(4,4-dimethoxytrityl)-2'-O-methylcytidine-3'-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite is used to incorporate 2-O-methyl modified nucleotides into oligonucleotides. It is a novel nucleoside analogue drug that inhibits tumor growth and activates RNA polymerase II promoter transcription. Group: Pharmaceutical. CAS No. 199593-09-4. Pack Sizes: 5 g. Product ID: B2706-086845. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Olaparib | Olaparib, also known as AZD-2281 or KU-59436, is a small-molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. Group: Pharmaceutical. CAS No. 763113-22-0. Pack Sizes: 1 g. Product ID: B0084-076683. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Pamiparib | Pamiparib is a potent and selective inhibitor of PARP1/PARP2 displaying anticancer activity. Uses: Poly(adp-ribose) polymerase inhibitors. Group: Pharmaceutical. CAS No. 1446261-44-4. Pack Sizes: 50 mg. Product ID: B2693-291315. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rifabutin | Rifabutin inhibits bacterial RNA polymerase. Group: Pharmaceutical. CAS No. 72559-06-9. Pack Sizes: 500 mg. Product ID: B0084-075984. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rifampicin | It is a semi-synthetic antibiotic of the rifamycin group. It is an inhibitor of bacterial RNA polymerase and has antibacerial activity. Uses: Antibiotics, antitubercular; enzyme inhibitors; leprostatic agents; nucleic acid synthesis inhibitors. Group: Pharmaceutical. CAS No. 13292-46-1. Pack Sizes: 100 g. Product ID: BBF-04562. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rucaparib | Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. So, rucaparib has been also found to be most effective in cells deficient in DNA repair, where the cells deficient are caused by exposure to genotoxic agents, such as irradiation produces DNA damage and its toxicity is augmented when the DNA repair is impaired. Increased radiosensitivity in presence of rucaparib was associated with persistent DNA breaks as determined by gamma-H2AX and p53BP1 foci. Rucaparib radiosensitizes prostate cancer cells, most effectively those that are PTEN-deficient and are expressing ETS gene fusion proteins, which inhibits NHEJ DNA repair. Uses: Cancer therapy. Group: Pharmaceutical. CAS No. 283173-50-2. Pack Sizes: 250 mg. Product ID: B2693-104639. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Rucaparib monocamsylate | Rucaparib camsylate is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which work in DNA repair process. It was approved for the treatment of ovarian cancer, and Rubraca is proved to be a monotherapy for the patients deleterious BRCA mutation associated advanced ovarian cancer who were treated with two or more chemotherapies. Group: Pharmaceutical. CAS No. 1859053-21-6. Pack Sizes: 100 mg. Product ID: B0084-007117. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Seliciclib | Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Mcl-1 belongs to the Bcl-2 family of antiapoptotic proteins and is a protein crucial to the survival of a range of tumor cell types. Group: Pharmaceutical. CAS No. 186692-46-6. Pack Sizes: 100 mg. Product ID: B1370-086385. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sofosbuvir | Sofosbuvir is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled sofosbuvir as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase. Uses: Antiviral agents. Group: Pharmaceutical. CAS No. 1190307-88-0. Pack Sizes: 2.5 g. Product ID: B0084-457411. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Talazoparib | Talazoparib, also known as BMN-673, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development. Uses: For research used only. Group: Pharmaceutical. CAS No. 1207456-01-6. Pack Sizes: 100 mg. Product ID: B0084-462689. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Thailanstatin A | Thailanstatin A is a splicesosome inhibitor that acts via suppressing RNA-polymerase II. It is effective against cancers, and can be used as a payload for ADCs. Group: Pharmaceutical. CAS No. 1426953-21-0. Pack Sizes: 5 mg. Product ID: B2695-292576. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Val-Cit-PAB-MMAE | Val-Cit-PAB-MMAE, a tubulin polymerase inhibitor, is a drug-linker conjugate for ADC. It contains an ADC linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE. Group: Pharmaceutical. CAS No. 644981-35-1. Pack Sizes: 100 mg. Product ID: BBF-05881. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Valganciclovir HCl | Valganciclovir hydrochloride hydrate is an antiviral used to treat cytomegalovirus infection. It is the prodrug of ganciclovir, a synthetic analog of 2'-deoxy-guanosine which is phosphorylated to a dGTP analog that competitively inhibits the incorporation of dGTP by viral DNA polymerase. Group: Pharmaceutical. CAS No. 175865-59-5. Pack Sizes: 2.5 g. Product ID: B0084-061144. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
